A detailed history of Patton Fund Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Patton Fund Management, Inc. holds 11,599 shares of VRTX stock, worth $5.23 Million. This represents 1.12% of its overall portfolio holdings.

Number of Shares
11,599
Previous 12,240 5.24%
Holding current value
$5.23 Million
Previous $5.74 Million 5.98%
% of portfolio
1.12%
Previous 1.22%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$460.0 - $505.78 $294,860 - $324,204
-641 Reduced 5.24%
11,599 $5.39 Million
Q2 2024

Jul 16, 2024

SELL
$392.81 - $485.53 $949,814 - $1.17 Million
-2,418 Reduced 16.5%
12,240 $5.74 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $5.98 Million - $6.54 Million
14,658 New
14,658 $6.13 Million
Q3 2023

Oct 31, 2023

SELL
$338.18 - $362.46 $1.43 Million - $1.53 Million
-4,220 Reduced 40.08%
6,309 $2.19 Million
Q2 2023

Jul 12, 2023

SELL
$314.42 - $351.91 $250,278 - $280,120
-796 Reduced 7.03%
10,529 $3.71 Million
Q1 2023

Apr 06, 2023

BUY
$283.23 - $323.1 $1.11 Million - $1.27 Million
3,933 Added 53.21%
11,325 $3.57 Million
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $84,299 - $94,836
-295 Reduced 3.84%
7,392 $2.13 Million
Q3 2022

Oct 21, 2022

BUY
$273.83 - $305.53 $2.1 Million - $2.35 Million
7,687 New
7,687 $2.23 Million
Q4 2020

Jan 29, 2021

SELL
$207.01 - $276.09 $1.27 Million - $1.69 Million
-6,129 Closed
0 $0
Q3 2020

Oct 20, 2020

SELL
$255.65 - $303.1 $9,970 - $11,820
-39 Reduced 0.63%
6,129 $1.67 Million
Q2 2020

Jul 08, 2020

BUY
$225.48 - $295.8 $1.39 Million - $1.82 Million
6,168 New
6,168 $1.79 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Patton Fund Management, Inc. Portfolio

Follow Patton Fund Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Patton Fund Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Patton Fund Management, Inc. with notifications on news.